key: cord-0019448-ahv81z7t
authors: Tang, Julian W.; Wu, Samantha; Kwok, Kin On
title: Can asia now learn from the experience of the west?
date: 2021-07-28
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.07.026
sha: 13460a872699411b7e4550794de8e4ebdb6b7f13
doc_id: 19448
cord_uid: ahv81z7t

nan

Over a year ago, we estimated the level of herd immunity required to prevent the exponential spread of SARS-CoV-2 in the populations of 32 countries. 1 This was when the COVID-19 pandemic was rapidly spreading across Europe and North America. Western countries are now successfully vaccinating their populations against SARS-CoV-2. Attention is currently turning to East and Southeast Asian regions where the virus was initially well controlled but now face record numbers of new cases.

Four jurisdictions -Japan, Vietnam, Thailand and Taiwan -that acted as exemplars of active case surveillance with digital contact-tracing are now seeing large surges in daily COVID-19 cases.

This has come against a background of low natural immunity, and a relatively slow vaccine rollout programme, with less than 5% of these populations having been vaccinated. Table 1 estimates the contributions to overall population immunity against COVID-19 for these four Asian populations (as of 20 May 2021), from natural and vaccine-induced immunity, compared to 13 other nations. The online data sources from which these estimates are derived, as listed in the Table footnotes, have some limitations. In particular, only the total numbers of vaccine doses are given. Exactly how these are distributed is determined by local and national agencies, and these details are not clear even in their own data (e.g. within the UK), especially where some singledose vaccines are used widely (e.g. the Johnson & Johnson vaccine in the USA). So we have taken a conservative approach and divided the total numbers of vaccine doses by 2, to indicate the number of people in each population that have been fully vaccinated, as most COVID-19 vaccines still follow a 2-dose regimen for complete vaccination. In addition, as different countries use different combinations of different COVID-19 vaccines, we have assigned an overall effectiveness of ~70%, as used elsewhere (see Table footnotes ). Similarly, for the estimate of the effectiveness of natural immunity from past SARS-CoV-2 infection, we have used previously published estimates of ~80%.

We then multiplied the number of people vaccinated with two vaccine doses by 0.70 and added this to the number of COVID-19 cases multiplied by 0.80, to estimate the overall number of people with immunity to the virus. For these estimates, we have not taken into account the numbers of deaths as these are mostly less than 2-3%, and the way that COVID-19-related deaths are defined varies significantly across different countries. Similarly, we have not used the 'Total recovered' data as listed in these websites, as this definition varies even more between countries, especially when long COVID syndrome is considered.

Based on our experience of the pandemic so far, all of these territories are potentially under threat from increased hospitalisations and deaths in populations aged 65 years and older, where the risk of death is several thousand times higher than in the teenage population. One aspect of the vaccination programme that has been learned in the West is the importance of completing both doses of the vaccines. Although there is some variability in the interval between the first and second doses, depending on supply and distribution, the second dose of a 2-dose regimen is essential for boosting and maintaining higher levels of antibodies and therefore vaccine protection, particularly in light of the more vaccine-escape capable variants, such as the delta (B.1.617.2, originally from India) and the beta (B.1.351, originally from South Africa) variants.

Of current concern, Japan's hosting of the Summer Olympics in Tokyo this July has the potential to import new variants from around the world, which may accelerate the spread amongst the largely unvaccinated, non-immune local population. These threats may explain why recent polls show that 60-80% of the Japanese population want the games to be cancelled. To avoid a repeat of the Western experience, we would therefore urge all these Asian territories (and others in a similar situation) to rapidly expand their COVID-19 vaccine programmes, and to persuade their populations to accept the COVID-19 vaccines.

Unfortunately there is a substantial degree of vaccine hesitancy amongst these four Asian populations, with the likelihood of COVID-19 vaccine uptake ranging from 41-83% according to Finally, if national lockdowns are applied, governments need to make adequate financial support readily available to people who are in monitored self-isolation or self-quarantine. In the absence of such support, compliance may be less sustainable. For example, in Taiwan, where a national lockdown is being imposed, government financial support also needs to cover those who are self-employed, as well as those employed by recognised companies and businesses.

Ultimately, each territory will decide which intervention will be best for their people.

However, given the experience in Western countries during 2020, only a national lockdown combined with the rapid rollout of a COVID-19 vaccination programme will effectively control the spread of the virus and reduce the risk of severe disease and death in the most vulnerable members of the population.

Transparency declaration: None of the authors have any conflicts of interest to declare. No funding was required for this article.

CRediT author statement: JWT conceived the article and wrote the first draft of the text and the Table. KKOK and SW provided additional country-specific input. All authors reviewed and critically assessed the final version of the submitted manuscript. 

Herd immunity -estimating the level required to halt the COVID-19 epidemics in affected countries

Willingness to Receive COVID-19 Vaccination in Japan

Knowledge About COVID-19, Beliefs and Vaccination Acceptance Against COVID-19 Among High-Risk People

International study: How many people will take the COVID vaccine?

Psychobehavioral Responses and Likelihood of Receiving COVID